Britons can be confident in vaccine monitoring, health secretary says
Reuters
Published Apr 08, 2021 07:45
Updated Apr 08, 2021 09:35
LONDON (Reuters) -Britons should be confident that the system to monitor COVID-19 vaccines is working following the change in advice on giving young people the Oxford-AstraZeneca jab, Health Secretary Matt Hancock said on Thursday.
"People can be reassured that we have the high class safety system run by our world class regulator (...) and then we're totally transparent with all of the side effects, no matter how extremely rare they are like these ones," he told Sky News.
Britain's vaccine advisory committee said on Wednesday that an alternative to Oxford-AstraZeneca's vaccine should be given to under 30s where possible due to a "vanishingly" rare side effect of blood clots in the brain.
Hancock said new guidance would not delay Britain's vaccination programme because alternatives from Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) would be available for the affected group.
Britain is aiming to give a first dose of COVID-19 vaccine all over-50s by mid-April and all adults by the end of July.
Hancock said there were 10.16 million people aged between 18 to 29, of whom 1.6 million had already had a first dose of vaccine.
"We have more than enough Pfizer and Moderna vaccines to cover all of the remaining eight and a half million people," he said.
"We are on track to hit the target that we've set that we will ensure every adult in the UK is offered the jab by the end of July."
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.